Immuno-oncological treatments

Immuno-oncological treatments refer to cancer treatments (drugs) whose purpose is to strengthen the body's own immune response against cancer.

Previously used immunomodulators include interferon, used for the treatment of cancers such as melanoma. The new-generation immuno-oncological treatments are based on a different mechanism. They, too, were first used for the treatment of melanoma. Research data used as the basis for a marketing authorisation have so far been reported for melanoma, lung cancer and kidney cancer. In addition, preliminary research results have been reported, and more extensive studies on a number of other cancers are underway.

Currently, these new-generation immuno-oncological drugs include the CTLA-4 antibody ipilimumab, the PD-1 antibody pembrolizumab and the PD-1 antibody nivolumab. In addition, there are many therapies that are still being studied and have not yet been launched on the market. Oncolytic viruses constitute another group of immuno-oncological therapies. The first of these therapies to achieve a marketing authorisation is talimogene laherparepvec.

Docrates a forerunner in immuno-oncological treatments

Docrates Cancer Center started immuno-oncological treatments already in March 2015, using pembrolizumab. After this, we have also started nivolumab treatments. In addition, we have started or are about to start a number of drug trials with immuno-oncological treatments. You will find more information about our ongoing clinical trials here. Docrates has gained experience in oncolytic adenovirus research and treatments since 2007. Docrates was the first European centre with a certification for oncolytic herpes virus treatments.

Read more

/

Colorectal cancer is a common but rarely talked-about disease

Colorectal cancer is the second most common cancer in Finland, and its level of incidence is increasing. Lifestyles and the...

Read more
/

Breakthroughs in follow-up cancer diagnostics: Recurring cancer can be detected before it reaches full speed

20.4.2023 | A liquid biopsy using markers released into the bloodstream by cancer cells can reveal the possible recurrence of...

Read more
/

Internal radiotherapy is an effective method of treatment for metastatic prostate cancer

14.3.2023 | Docrates Cancer Center studied the effectiveness of 177Lu-PSMA treatment with a 4-week treatment interval for patients with metastatic...

Read more
/

The number of insured patients has more than tripled in five years

9.3.2023 | In 2022, nearly 30% of revenue generated by Docrates Cancer Center’s Finnish patients came from insurance company customers,...

Read more

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
358 10 773 2010

Contact us!

Mon-Thu 8 am-6 pm, Fri 8 am-4 pm (local time)